Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKC202 + limertinib versus platinum-doublet chemotherapy in EGFR-mutant, MET-amplified/overexpressing advanced non-small cell lung cancer after EGFR-TKI failure
CTR20252935Phase 3Active
- Sponsor
- Aosaikang Biotherapeutics
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of askc202 and limertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Aosaikang Biotherapeutics. Primary endpoint: Progression-free survival. Started Sep 2025; status: active.
02
Drugs
askc202limertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20252935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252935.